Biopharma Manufacturing For Advanced Therapies: A Panel Discussion

While new biologic modalities hold great potential as powerful therapeutic tools, they also pose several manufacturing and development hurdles that the biomanufacturing industry is actively working to overcome. Companies are tasked with improving and expanding upon current process development models, all the while managing limitations in capacity and supply chain constraints.

In a Financial Times panel discussion organized in partnership with Cytiva, experts in this fast-growing field discussed ways to improve biomanufacturing processes to help ensure the next generation of advanced therapies is both accessible and affordable to patients. Explore highlights from the panel discussion on the key challenges of scalability, automation, and flexibility.